Shots:
- NANOBIOTIX & Janssen have amended their 2023 collaboration to develop & commercialize JNJ-1900 (NBTXR3), adjusting the deal value from $2.7B to $2.6B
- As per the revision, NANOBIOTIX will receive ~$1.77B in milestones related to cisplatin-ineligible HNSCC & inoperable stage 3 NSCLC, with ~$165M in milestones for China, South Korea, Singapore, & Thailand. J&J will cover all remaining P-III (NANORAY-312) costs, with NANOBIOTIX covering only a small portion
- Amendment extends NANOBIOTIX’s cash runway to mid-2026, with potential for 2027 via non-dilutive financing, while reducing cash burn, as P-III trial accounted for major portion of company’s operating costs
Ref: NANOBIOTIX | Image: NANOBIOTIX & Janssen
Related News:- NANOBIOTIX Signs a License Agreement with Janssen to Co-Develop and Commercialize NBTXR3
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
